LONDON, July 26 (Reuters) - Obesity drugs will not join the World Health Organization's (WHO) latest essential medicines list, but treatments for diseases, including Ebola and multiple sclerosis will, documents published by the U.N. agency showed.
A medication currently used to treat insomnia may also be effective in preventing alcohol intake and relapse in alcohol use disorder, according to researchers at the Florey Institute of Neuroscience and Mental Health.
Pharnext, a French biotech, has mainly used the platform so far to single out combinations of already-approved drugs that work well together. This approach spawned two clinical-stage assets, a phase 3 program targeting Charcot-Marie-Tooth disease and a combination of muscle relaxant baclofen and anti-alcohol agent acamprosate that is set to enter a phase 2b in Alzheimer’s disease patients later this year.
Angelini Fine Chemicals: new synthesis technologies to broaden the offer